Страна: Австралия
Язык: английский
Источник: Department of Health (Therapeutic Goods Administration)
atropine sulfate monohydrate, Quantity: 600 microgram/mL; sodium hydroxide
Juno Pharmaceuticals Pty Ltd
Injection, solution
Excipient Ingredients: water for injections; sodium chloride; sulfuric acid
Subcutaneous, Intramuscular, Intravenous
1mL x 50, 1mL x 10
(S4) Prescription Only Medicine
INDICATIONS AS AT 30 SEPTEMBER 2003:Surgery : Atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. The use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. After surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. Cardiopulmonary resuscitation : Atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. Anticholinesterase Poisoning : Atropine Juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, Amanita muscaria mushrooms or other compounds with anticholinesterase activity. A cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.
Visual Identification: Clear, colourless, particle-free solution.; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2022-07-05
_ _ 1 ATROPINE JUNO INJECTION BP _(Atropine sulfate monohydrate) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Atropine Juno Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking Atropine Juno Injection against the benefits this medicine is expected to have for you. This medicine is likely to be used while you are at the clinic or in hospital. If possible, please read this leaflet carefully before this medicine is given to you. In some cases this leaflet may be given to you after the medicine has been used. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT ATROPINE JUNO INJECTION IS USED FOR Atropine sulfate monohydrate belongs to a group of medicines called antimuscarinic agents. Atropine Juno Injection is given before anaesthesia to decrease mucus secretions, such as saliva. During anaesthesia and surgery, atropine is used to help keep the heart beat normal. Atropine sulfate monohydrate is also used to block or reverse the adverse effects caused by some medicines and certain type of pesticides. Atropine Juno Injection may be used for the management of other conditions that are not mentioned above. Your doctor will be able to tell you about the specific condition for which you have been prescribed Atropine Juno Injection. This medicine is available only with a doctor's prescription. BEFORE YOU ARE GIVEN ATROPINE JUNO INJECTION _WHEN YOU MUST NOT BE _ _GIVEN IT _ DO NOT USE ATROPINE JUNO INJECTION IF YOU HAVE AN ALLERGY OR HAVE HAD AN UNUSUAL REACTION TO ATROPINE OR ANY OF THE ANTICHOLINERGIC MEDICINES SUCH AS HYOSCYAMINE AND BELLADONNA. DO NOT USE ATROPINE JUNO INJECTION IF YOU HAVE OR HAVE HAD ANY MEDICAL CONDITIONS, ESPECIALLY THE FOLLOWING: • severe and chronic inflammation of the large intestine and r Прочитать полный документ
Juno Pharmaceuticals Pty Ltd Australian Product Information PI v 1.0 Page | 1 AUSTRALIAN PRODUCT INFORMATION ATROPINE JUNO (ATROPINE SULFATE MONOHYDRATE 600 MICROGRAM / 1 ML) _ _ 1 NAME OF THE MEDICINE Atropine sulfate monohydrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 0.6 mg/mL injection: a clear, colourless, sterile solution containing 0.6 mg/mL atropine sulphate. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS. 3. PHARMACEUTICAL FORM Clear colourless particle free solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS SURGERY Atropine Juno may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. The use of Atropine Juno as an antisialagogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. Atropine Juno may be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects when they are used after surgery to terminate curarisation. CARDIOPULMONARY RESUSCITATION It may be used in the management of patients with sinus bradycardia who have associated hypotension and increased ventricular irritability. ANTICHOLINESTERASE POISONING Atropine Juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, _ Amanita muscaria_ mushrooms or other compounds with anticholinesterase activity. A cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently. 4.2 DOSE AND METHOD OF ADMINISTRATION Atropine Juno may be administered by subcutaneous (SC), intramuscular (IM) or direct intravenous (IV) injection. Atropine Juno contains no antimicrobial agent. It should be used only once in one patient only and any residue discarded. Atropine Juno should not be added to any IV infusion solution. Juno Pharmaceuticals Pty Ltd Australian Product Information PI v 1.0 Page | 2 SURGERY Adults: 300-600 µg of atropine sulfate IM or SC, Прочитать полный документ